证券日报网讯 12月4日，新华医疗在互动平台回答投资者提问时表示，公司2025年度主要指标预算为国 际营业收入与2024年度相比增长不低于30%。 （文章来源：证券日报） ...

证券日报网讯 12月4日，新华医疗在互动平台回答投资者提问时表示，公司严格按照证券监管的相关规 定进行信息披露，公司重视市值管理，正积极通过控股股东增持、优化分红、完善治理结构、实施股权 激励等方式方法进行市值管理。 （文章来源：证券日报） ...

证券日报网讯12月4日，新华医疗（600587）在互动平台回答投资者提问时表示，公司已发布减持公 告，自新华医疗董事会决议之日起12个月内，华佗国际通过公开市场交易方式减持华检医疗不超过5% 股份。 ...

证券日报网讯 12月4日，新华医疗在互动平台回答投资者提问时表示，公司股票回购注销事宜需结合公 司未来经营规划、资金状况等多方面因素综合研判。后续若有相关安排，公司将严格按照信息披露规则 履行披露义务。 （编辑 姚尧） ...

12月4日的资金流向数据方面，主力资金净流入317.43万元，占总成交额6.03%，游资资金净流入91.26 万元，占总成交额1.73%，散户资金净流出408.7万元，占总成交额7.77%。 近5日资金流向一览见下表： | | | | | 日期 收盘价 涨跌幅 主力净流入 主力净占比 游资净点比 游资净占比 散户净占比 | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 2025-12-04 | 15.04 | 0.33% | 317.43万 | 6.03% | 91.26万 | 1.73% | -408.70万 | -7.77% | | 2025-12-03 | | 14.99 -0.66% | 376.97万 | 5.31% | 803.67万 | 11.33% | -1180.64万 | -16.65% | | 2025-12-02 | 15.09 | -1.11% | -727.10万 | -11.66% | 618.03万 | 9.91% | 109.07万 | 1.75% | | 2025-12-01 | 15.2 ...

（记者 王晓波） 每经AI快讯，有投资者在投资者互动平台提问：公司的外骨骼机器人开始临床试验了吗？ 新华医疗（600587.SH）12月4日在投资者互动平台表示，2025年1月26日，公司下肢助行外骨骼机器人 收到国家知识产权局专利申请受理通知书。目前医院级产品现处于功能样机研发阶段，预计2026年完成 产品研发，2027年取得医疗器械注册证，该产品支持医院、社区、家庭及养老机构等多场景应用。 ...

Group 1 - China Pacific Insurance has received approval from the financial regulatory authority for Wang Yuhua to serve as a director [1] - Shanghai Bank announced that the regulatory authority has approved Chen Lei's qualification as vice president [2] - Shanghai HuGong has decided to terminate the "Aerospace Equipment Manufacturing Base" fundraising project due to significant changes in project feasibility [3] Group 2 - Dongwang Times plans to reduce its stake by up to 1.20% through share sales [4] - Zhinancun intends to increase its capital by 100 million yuan in its wholly-owned subsidiary, Maigao Securities [5] - Jinxinnong reported a sales revenue of 115 million yuan from pig sales in November [6] Group 3 - Tiantan Biological has completed the Phase III clinical trial of its human prothrombin complex, showing good efficacy and safety for hemophilia B patients [7] - Beijete's subsidiary has signed a framework agreement for equity acquisition to gain control of Yunnan Wenye Nonferrous Metals [8] - Zhongsheng Pharmaceutical's RAY1225 injection has received approval for a new clinical trial indication for treating metabolic-associated fatty liver disease [9] Group 4 - Enhua Pharmaceutical's hydrochloride sulpiride tablets have passed the consistency evaluation for generic drugs [10] - Shenkong Co. plans to invest 60 million yuan in a semiconductor industry fund [11] - Lianhuan Pharmaceutical's subsidiary has received approval for its drug to pass the consistency evaluation for generic drugs [12] Group 5 - Dazhong Transportation has received approval to issue debt financing tools totaling 4.5 billion yuan [13] - Jintian Titanium Industry plans to invest 50 million yuan in an industry merger and acquisition fund [14] - Changchun Gas has committed over 1.7 billion yuan to gas facility upgrades [15] Group 6 - Laimei Pharmaceutical's innovative anti-cancer drug "Nano Carbon Iron" has received approval for clinical trials [16] - Longquan Co. has signed supply contracts worth approximately 50.76 million yuan for nuclear power components [17] - Igor plans to distribute a cash dividend of 1 yuan per 10 shares [18] Group 7 - Xingfa Group's subsidiary has signed a processing agreement for 80,000 tons of lithium iron phosphate [20] - Yunjigroup's director Wang Wanfeng has resigned for personal reasons [21] - Saiseng Pharmaceutical's application for the listing of a new drug has been accepted by the regulatory authority [22] Group 8 - Xinhua Medical has obtained registration certificates for two new medical devices [23] - Chaoying Electronics plans to invest 100 million USD in its Thai subsidiary for an AI circuit board expansion project [24] - Suzhou Planning's application to acquire 100% of Dongjin Aviation has been accepted by the Shenzhen Stock Exchange [25]

每经AI快讯，有投资者在投资者互动平台提问：请问在外骨骼机器人方面，公司对发展前景如何看 待？投入情况和取得成果，请简单介绍下。 （文章来源：每日经济新闻） 新华医疗（600587.SH）12月4日在投资者互动平台表示，随着国内人口老龄化程度的不断加深，康复 需求持续增长，下肢外骨骼康复机器人作为康复机器人市场的重要组成部分，其市场份额也在不断扩 大。近年来，随着医疗行业的快速发展，国家出台了一系列政策、法律和法规，也为下肢外骨骼康复机 器人的发展提供了重要的政策支持和保障。公司高度重视外骨骼机器人的发展，已组建涵盖机械、控 制、康复医学等多学科的专业研发团队，并持续投入研发资源。截至目前，已在外骨骼结构轻量化、关 节驱动控制、步态轨迹生成等关键技术上实现突破，为产品化奠定了扎实基础。 ...

格隆汇12月4日丨新华医疗(600587.SH)在投资者互动平台表示，新华医疗目前无回购计划。 ...

（记者 王晓波） 每经AI快讯，有投资者在投资者互动平台提问：大盘即将站上4000点。公司在4000点回购是不是认为 风险太大？ 新华医疗（600587.SH）12月4日在投资者互动平台表示，新华医疗目前无回购计划。 ...